MARTINSRIED, Germany, May 5, 2009 (GLOBE NEWSWIRE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment:TecDAX) announced today that it has received a milestone payment from its collaboration with Novartis. The payment was triggered by Novartis filing of the necessary documentation to initiate a Phase 1 clinical trial with a HuCAL-derived fully human antibody. This is the second HuCAL antibody to enter clinical trials within MorphoSys’s alliance with Novartis.
